#bright_minds_biosciences a #biotechnology_company focused on developing novel drugs for the targeted treatment of #neuropsychiatric_disorders, #epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, Dr. Revati Shreeniwas, Chief Medical Officer, Professor John McCorvy, PhD, Senior Advisor, and other key speakers will host a symposium on the recent therapeutic developments within the Dravet Syndrome landscape. https://bit.ly/3wL3n38
Like
Comment
Share
